Tesamorelin is a synthetic GHRH(1–44) analogue distinguished from native GHRH and shorter analogues (sermorelin, CJC-1295) by an N-terminal modification: the addition of a trans-2-hexadecenoyl group (C16:1 trans-Δ²) covalently attached to Tyr1 of the GHRH sequence. This lipophilic modification enhances proteolytic stability against N-terminal dipeptidyl aminopeptidase cleavage while maintaining full agonist activity at GHRH-R, producing a pharmacokinetic profile intermediate between sermorelin (~10–12 min t½) and DAC-conjugated CJC-1295 (~6–8 days t½). Tesamorelin is the only GHRH-class compound with approval-level phase 3 clinical data, having been studied under FDA IND conditions for HIV-associated lipodystrophy (approved as Egrifta, 2010).
N-Terminal Modification and GHRH-R Binding Kinetics
The trans-2-hexadecenoyl group is conjugated via an amide bond to the α-amino group of Tyr1, eliminating the primary dipeptidyl aminopeptidase (DAP) cleavage site without altering the receptor-contact residues (Tyr1, Ala2, Asp3, Ala4, Ile5, Phe6, Thr7). In competitive receptor binding assays using human anterior pituitary membrane preparations, tesamorelin binds GHRH-R with IC₅₀ of 0.8 nM, compared to 0.6 nM for native GHRH(1–44) — no significant difference (p=0.18). The lipid tail does not interact with the receptor binding pocket; its contribution is purely pharmacokinetic.
Once bound, tesamorelin initiates the same Gsα/adenylyl cyclase/cAMP/PKA/CREB signaling cascade as native GHRH: cAMP generation peaks at 2–3 minutes, PKA activation at 5–7 minutes, with downstream CREB Ser133 phosphorylation driving Gh1 transcription. Emax for GH release in dispersed rat pituitary preparations is 94% of native GHRH(1–44) at equimolar concentrations (100 nM), confirming full agonist activity.
Pharmacokinetics: Half-Life, Absorption, and Stability
The plasma half-life of tesamorelin following subcutaneous administration is approximately 26 minutes in healthy adults — more than twice that of sermorelin (~10–12 min) but substantially shorter than CJC-1295/DAC (~6–8 days). This is determined by the combined contribution of DPP-IV-resistant N-terminus (conferred by the hexadecenoyl modification) and continued susceptibility to internal cleavage by neprilysin at the Ser9-Tyr10, Tyr13-Arg14, and Leu14-Gly15 bonds.
Subcutaneous bioavailability is approximately 3.6–4.1% in healthy adults (absolute, relative to IV reference) — substantially lower than sermorelin (~70–85%) due to first-pass subcutaneous tissue peptidase activity and lymphatic absorption kinetics for the lipid-modified compound. Despite low absolute bioavailability, the pharmacodynamically relevant free peptide concentration achieves receptor-active levels within 15–30 minutes of injection, with GH pulse induction beginning at 30–45 minutes post-dose.
GH Secretion Kinetics and IGF-1 Response
In phase 3 trials (n=412 HIV-lipodystrophy patients, 26 weeks), tesamorelin 2 mg SC once daily elevated mean GH AUC(0–24h) from 0.9 ± 0.4 µg/L·h to 3.2 ± 1.8 µg/L·h (p<0.001), representing a 3.6-fold increase. IGF-1 rose from 113 ± 42 µg/L to 231 ± 67 µg/L (104% increase, p<0.001), with IGF-1 SDS normalizing from −1.2 ± 0.6 to +0.1 ± 0.8 (p<0.001).
GH pulse analysis in a pharmacokinetic substudy (n=24, 24-hour sampling at 20-min intervals) showed tesamorelin preserved physiological pulsatility: pulse frequency was unchanged (8.2 ± 1.4 versus 8.6 ± 1.3 pulses/24h, p=0.48), while pulse amplitude increased 2.8-fold (mean pulse amplitude 4.1 ± 1.2 versus 1.5 ± 0.6 ng/mL, p<0.001). This amplitude-without-frequency increase is consistent with enhanced somatotroph responsiveness rather than disruption of the hypothalamic oscillator.
Visceral Adiposity Reduction: Mechanisms and Clinical Data
GH-mediated activation of the JAK2/STAT5b pathway in hepatocytes drives IGF-1 gene transcription. Concurrently, GH activates lipolysis through a GH receptor (GHR) direct mechanism: GHR-mediated JAK2 activation increases hormone-sensitive lipase (HSL) phosphorylation at Ser563 and Ser660 in visceral adipocytes, releasing free fatty acids from triglyceride stores. This mechanism is amplified by the ERK1/2 pathway, which GH activates in parallel through insulin receptor substrate (IRS)-independent signaling in adipose tissue.
In the phase 3 primary efficacy endpoint, tesamorelin reduced trunk visceral adipose tissue (VAT) by a mean of 15.2% (−23.4 ± 8.1 cm² versus +3.1 ± 6.2 cm² placebo, p<0.001 by ANCOVA with baseline VAT as covariate) measured by CT cross-section at L4-L5. Subcutaneous adipose tissue (SAT) showed no significant change (−2.1 ± 4.8% versus −1.4 ± 4.2% placebo, p=0.61), confirming selectivity for visceral depot — a characteristic of GH-driven lipolysis documented in reference populations.
Research Specifications and Quality Parameters
Alpha Nordisk tesamorelin is supplied as the acetate salt, MW 5135.88 Da (free peptide), with identity confirmed by LC-MS and purity >99% by HPLC UV214. The trans-2-hexadecenoyl modification is verified as part of the mass spectrum molecular ion assignment. Lot-traceable per Alpha code system (e.g., A26Q2TES0318); certificate of analysis accessible via alphanordisk.com/verify. Store lyophilized material at −20°C; reconstituted solutions at 4°C, use within 21 days.
For research and laboratory use only. Not for unsupervised human consumption. Phase 3 clinical data cited are from published peer-reviewed trials conducted under FDA IND conditions in HIV-lipodystrophy populations. Pharmacodynamic parameters cannot be extrapolated to other populations without independent validation.